BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/15/2022 9:40:09 AM | Browse: 667 | Download: 1896
 |
Received |
|
2021-10-09 14:24 |
|
Peer-Review Started |
|
2021-10-09 14:26 |
|
First Decision by Editorial Office Director |
|
2021-12-12 08:13 |
|
Return for Revision |
|
2021-12-12 08:13 |
|
Revised |
|
2022-01-04 11:11 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-14 05:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-16 07:29 |
|
Articles in Press |
|
2022-02-16 07:29 |
|
Edit the Manuscript by Language Editor |
|
2022-02-09 16:37 |
|
Typeset the Manuscript |
|
2022-04-01 07:31 |
|
Publish the Manuscript Online |
|
2022-04-15 09:40 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Jie Xu, Peng Zhang, Jin-Long Hu, Hong Liang, Yan-Yan Zhu, Yao Cui, Po Niu, Min Xu and Ming-Yue Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Henan Provincial Department of Science and Technology |
212102310047 |
|
| Corresponding Author |
Ming-Yue Liu, Doctor, MD, PhD, Chief Doctor, Department of Oncology, Henan Provincial People's Hospital, No.7 Weiwu road, Zhengzhou 450003, Henan Province, China. 1816160187@e.gzhu.edu.cn |
| Key Words |
Colorectal neoplasms; Microsatellite stable; Programmed cell death-1 inhibitor; Platelet-to-lymphocyte ratio; Regorafenib; Progression-free survival |
| Core Tip |
The use of regorafenib combined with programmed cell death-1 inhibitor in the treatment of refractory microsatellite stable colorectal cancer has contradictory results in some small-scale studies. The purpose of this paper is to analyze the real-world data of our center in the past 2 years so as to provide more treatment experience and reference for treatment selection. The progression-free survival and overall survival of patients with refractory microsatellite stable colorectal cancer treated with regorafenib combined with programmed cell death-1 inhibitor were analyzed retrospectively, and the safety and adverse reactions under different doses were reviewed. The platelet-to-lymphocyte ratio was found as a potential screening index for patients with prolonged progression-free survival. |
| Publish Date |
2022-04-15 09:40 |
| Citation |
Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the predictive value of platelet-to-lymphocyte ratio on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i4/920.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i4.920 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
